SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Hands holding crystal ball fortune telling collage art. Abstract concept of prophecy and prediction of future illustration
FDA
Krystal Biotech’s FDA Platform Designation Pushes Limits of the Award
The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation based on its approved topical skin cream. What this will mean for Krystal’s still-in-development eye drop is unclear.
October 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
IN PARTNERSHIP WITH ELEMENT
Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma
In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players are rethinking their strategies amid global supply chain disruption.
October 21, 2025
 · 
1 min read
 · 
BioSpace Insights
Business people and concepts vector art exit
Cell therapy
Galapagos Exits Cell Therapy, Cuts 365 Employees
Galapagos at the start of the year had planned to split into two businesses, with one resulting entity focused on cell therapies. The biotech nixed these plans a few months later, instead choosing to put up for sale multiple cell therapy assets.
October 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration showing businessman trying to create his own road
Cancer
Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA
With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for zanzalintinib.
October 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Hand holding a lung shape symbol against a blue background. World tuberculosis day, world no tobacco day, lung cancer, pulmonary hypertension, pneumonia
Lung cancer
Summit Eyes 2025 FDA Application for Ivonescimab Despite Overall Survival Miss
In May, Summit released early data from the Phase III HARMONi study showing that while the PD-1/VEGF inhibitor resulted in significant progression-free survival improvements, it fell short of the overall survival bar.
October 21, 2025
 · 
2 min read
 · 
Tristan Manalac
business graph chart finance stock market collage hand halftone trendy. vector illustration concept growth investment exchange currency money financial. technology digital background profit trade.
Metabolic disorders
Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath
The death occurred in a patient who had a complex medical background and who was being managed with several drugs, according to RBC Capital.
October 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: an RNA Molecule/iStock, Artur Plawgo
Manufacturing
Companies Confront Challenge of Making Bespoke mRNA Therapies Fast
To tailor cancer therapies to individual patients, Moderna, BioNTech and other companies are rethinking how they optimize manufacturing schedules and resources.
October 21, 2025
 · 
4 min read
 · 
Nick Paul Taylor
World kidney day. Human hands holding healthy kidney shape made from paper on light blue background.
Autoimmune disease
Roche’s Gazyva Expands Out of Cancer With FDA Approval for Lupus
The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of action gives it activity in improving kidney conditions in patients with lupus nephritis.
October 20, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
The white plane flies against the blue sky, leaving a white trail. Vector illustration
FDA
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug
Last month, investors’ hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.
October 20, 2025
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS